Basal cell carcinoma (BCC) accounts for 80% of skin cancer cases. Although mostly curable by simple excision, the treatment of advanced disease can be challenging, as curative surgery or radiotherapy may not always be feasible. The scope of this review is to summarize current knowledge on molecular mechanisms in BCC pathogenesis, to elaborate on the definition of advanced/difficult-to-treat BCC, and to outline systemic treatment options. Particularly, pivotal trial data of the approved hedgehog inhibitors (HHI) sonidegib and vismodegib are compared. Concluding, we provide an overview of novel, particularly neoadjuvant and combined treatment approaches, both with hedgehog and immune-checkpoint inhibitors.
基底细胞癌（BCC）占皮肤癌病例的80%。虽然多数病例可通过简单切除治愈，但晚期疾病的治疗可能具有挑战性，因为根治性手术或放疗并非总是可行。本综述旨在总结当前关于BCC发病分子机制的认识，详细阐述晚期/难治性BCC的定义，并概述系统性治疗方案。特别对已获批的刺猬通路抑制剂（HHI）索尼德吉和维莫德吉的关键试验数据进行了比较。最后，我们综述了新型治疗方案，特别是涉及刺猬通路抑制剂与免疫检查点抑制剂的辅助治疗及联合治疗策略。
Therapeutic Approaches for Advanced Basal Cell Carcinoma: A Comprehensive Review
肿瘤(癌症)患者之家